Monday, October 22, 2007

Follow-up on Prempro Trial

An Associated Press story in today's Reno Gazette Journal follows up on the Nevada Prempro plaintiffs' verdict.  The main point of the article -- No alarm on Wall Street over Wyeth case -- is that the financial markets are not particularly concerned about the litigation over the Prempro and Premarin hormone replacement therapy (HRT) drugs, and are treating the $134 million verdict ($35 million compensatory damages and $99 million punitive damages) more as an aberration than an omen.  As one financial analyst put it, as quoted in the article, "Unlike Wyeth's diet drug litigation, the Premarin/Prempro is widely viewed as more of a headline risk than a long-term financial risk."  Of course, after fen-phen, almost any Wyeth litigation risk would appear small by comparison.

HME

http://lawprofessors.typepad.com/mass_tort_litigation/2007/10/follow-up-on-pr.html

Prempro | Permalink

TrackBack URL for this entry:

http://www.typepad.com/services/trackback/6a00d8341bfae553ef00e54f1077f88834

Listed below are links to weblogs that reference Follow-up on Prempro Trial:

» "No alarm on Wall Street over Wyeth case" from PointOfLaw Forum
Per the AP (via Erichson), markets are shrugging off the $134 million Nevada judgment (see Oct. 11) against the maker of the hormone-replacement drugs Prempro and Premarin. Earlier coverage of Wyeth victories is here, here and here. One stock analyst,... [Read More]

Tracked on Oct 28, 2007 9:24:19 PM

Comments

Post a comment